



# Biological insights from large-scale protein copy number measurements



David O'Connor

Centre for Proteomic Research  
University of Southampton, UK

# Plan of talk



- The case for absolute quantification
- Which absolute quantification method?  
Use of a data-independent acquisition approach
- What can you do with such data?  
Case history – *Chlamydia trachomatis*

# Better Quantification





Absolute versus relative quantification




# Advantages of Absolute Quantification

Measuring numbers of molecules/cell gives more information

[Protein]  
State 1



[Protein]  
State 2




Significant

Noise?

# Advantages of Absolute Quantification

Data loss associated with relative quantification (2-D gels, SILAC, iTRAQ etc.)



|           | Spot Volume |         | $\frac{\text{Test}}{\text{Control}}$ |
|-----------|-------------|---------|--------------------------------------|
|           | Test        | Control |                                      |
| Protein A | 100.1       | 125.2   | 0.8                                  |
| Protein B | 2160.3      | n.d.    | ?                                    |


# Advantages of Absolute Quantification

Ranking proteins in terms of molecules/cell can be useful...

| RANK | PROTEIN   | MOLECULES/CELL  |
|------|-----------|-----------------|
| 1    | Protein A | $1 \times 10^7$ |
| 2    | Protein B | $1 \times 10^6$ |
| 3    | Protein C | $1 \times 10^5$ |
| 4    | Protein D | $1 \times 10^4$ |
| 5    | Protein E | $1 \times 10^3$ |
| .    | .         | .               |
| .    | .         | .               |
| .    | .         | .               |
| 25   | Protein Y | $<10$           |
| 26   | Protein Z | $<10$           |

POTENTIAL AS  
DRUG TARGET?

Bad



Good

# Advantages of Absolute Quantification


Identifying and ranking factors that determine protein abundance...



E.g. codon usage, length, hydrophilicity, pI, [mRNA], location of gene in genome etc.

# Advantages of Absolute Quantification

Finding out where a cell is investing its energy




E.g. protein synthesis consumes ca. two-thirds of the total energy produced by a rapidly growing *Escherichia coli* cell



# Plan of talk

- The case for absolute quantification



- Which absolute quantification method?


Use of a data-independent acquisition approach

- What can you do with such data?

Case history – *Chlamydia trachomatis*

# Which absolute quantification method?


Use of a data-independent acquisition (DIA) strategy



Review: Vaudel, M. *et al.* (2010) Protein and peptide quantification: a map of the minefield *Proteomics* 10: 650-670.

# Which absolute quantification method?


## Limitations of a data-dependent acquisition (DDA) strategy



- Only 7 out of 27 labs identified all 20 proteins correctly
- Only one lab saw all proteotypic peptides – why?

# Which absolute quantification method?


## Limitations of a data-dependent acquisition (DDA) strategy



- Serial selection of precursor ions biases analysis to high abundance components
- Precursor ion scans are stochastic - different ions may be selected for fragmentation in different runs → irreproducibility
- Selection windows of 2-4 Da means additional precursor may be selected for fragmentation along with target ion → lower signal:noise


# 'Traditional' LC - Tandem Mass Spectrometry

## One slice at a time







# Label-free proteomics

## Principle of LC-MS<sup>E</sup>





# Label-free proteomics

## Principle of LC-MS<sup>E</sup>



Reconstruct product ion spectra by Time Alignment



# Plan of talk

- The case for absolute quantification
- Which absolute quantification method?  
Use of a data-independent acquisition approach
- ➔ ■ What can you do with such data?  
Case history – *Chlamydia trachomatis*



# *Chlamydia trachomatis*

A widespread and important pathogen




[http://www.nature.com/eye/journal/v19/n10/fig\\_tab/6701963f5.html](http://www.nature.com/eye/journal/v19/n10/fig_tab/6701963f5.html)

- Causes trachoma - the leading cause of preventable blindness
- ~84 million people have active infection
- Also major cause of genital tract infections – leads to pelvic inflammatory disease and tubal factor infertility

# Life cycle of *Chlamydia trachomatis*

## Elementary Bodies ↔ Reticulate Bodies



# *Chlamydia trachomatis*

## Elementary Bodies and Reticulate Bodies



### EBs



- Extracellular, infectious form
- Metabolically quiescent

### RBs

- Intracellular, non-infectious
- Active, replicating stage

# Label-free proteomics

## Dynamic range and reproducibility



$R^2 = 0.9967$


Technical replicates: ~12% CV

Biological replicates: ~ 16% CV



# Label-free proteomics


## Dynamic range and reproducibility



# Label-free proteomics

## Peptides used to assign proteins – LC-MS<sup>E</sup> vs. iTRAQ

|                    | Average number of peptides per protein | Sequence coverage (%) |
|--------------------|--|-----------------------|
| iTRAQ              | 10                                     | 26                    |
| LC-MS <sup>E</sup> | 46                                     | 64                    |




# Label-free proteomics

## Top ten most abundant proteins in EBs

| <b>Locus</b> | <b>Gene name</b> | <b>Protein description</b>          | <b>EB<br/>(molecules/cell)</b> |
|--------------|------------------|-------------------------------------|--------------------------------|
| CTL0050      | <i>ompA</i>      | major outer membrane protein        | 272,790                        |
| CTL0574      | <i>tufA</i>      | translation elongation factor Tu    | 215,611                        |
| CTL0652      | <i>dnaK</i>      | chaperone protein                   | 166,008                        |
| CTL0365      | <i>hsp60_1</i>   | chaperonin GroEL                    | 130,043                        |
| CTL0803      | <i>mip</i>       | peptidyl-prolyl cis-trans isomerase | 129,190                        |
| CTL0847      |                  | conserved hypothetical protein      | 114,533                        |
| CTL0568      | <i>rplL</i>      | LSU ribosomal protein L12P (L7/L12) | 100,628                        |
| CTL0887      |                  | putative exported protein           | 84,041                         |
| CTL0874      |                  | conserved hypothetical protein      | 80,739                         |
| CTL0488      | <i>acpP</i>      | acyl carrier protein                | 66,243                         |



# Label-free proteomics

Proteins that are differentially expressed between EBs and RBs






# Glycolysis




# TCA cycle



**Enzymes down-regulated in EBs**


# Label-free proteomics

Proteins that are differentially expressed between EBs and RBs



# Where *Chlamydia trachomatis* invests its ATP

## Energy expenditure by functional category



# Quantification of the *Chlamydia trachomatis* proteome

## Some conclusions



- Absolute quantification of most of predicted proteome in both RBs and EBs
- Rank order of expression reveals hitherto hypothetical proteins are among the most abundant in Chlamydia
- Dynamic expression range of >3 logs - 37 pg (AMP nucleosidase) to 29 ng (MOMP).
- EBs appear to have full complement of proteins even though metabolically quiescent
- Levels of most proteins are down in EBs but some accumulate (in anticipation of infection?)

# Quantification of the *Chlamydia trachomatis* proteome

## Some conclusions (cont.)

- LC-MS<sup>E</sup> provides more extensive and robust qualitative and quantitative data relative to iTRAQ
- >71% of predicted *C. trachomatis* proteome is expressed during transition from RB to EB
- Absolute quantification data obtained for >62% of predicted proteome
- Differential expression data indicates *C. trachomatis* shuts down metabolic activity during the transition from RB to EB (e.g. glycolysis, TCA)
- Cell wall enzymes expressed in RBs – suggests novel role
- Majority of energy invested in protein translation machinery, one cell surface component and many hypothetical proteins



# Label-free quantification

## Some key challenges and issues

- Given sensitivity of detection is  $<10$  molecules/cell, why is 'only' 71% of predicted proteome detected?
- Use of LC-MS<sup>E</sup> for the quantification of PTMs?
- Faster cycling rate for MS<sup>E</sup> ( $>10$  Hz)?
- Multiplexing of LC-MS<sup>E</sup> analyses?

# Biological insights from large-scale protein copy number measurements

## Acknowledgements

- Paul Skipp (CPR)
- Erika Parkinson (CPR)
- Pete Boyd (CPR)
- Shannon Pead (CPR)
- Ian Clarke (SGH)
- Lesley Cutcliffe (SGH)
- Jim Langridge (Waters)
- Chris Hughes (Waters)
- Therese McKenna (Waters)
- Simon Harris (Sanger)
- Helena Seth-Smith (Sanger)
- Nick Thomson (Sanger)

Funders: BBSRC, EU, MRC, NIHR, Unilever plc, Wellcome Trust